Format

Send to

Choose Destination
Prog Mol Biol Transl Sci. 2019;165:63-106. doi: 10.1016/bs.pmbts.2019.05.001. Epub 2019 Jun 8.

AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.

Author information

1
Centre for Studies on the Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, Montréal, Canada; McGill University, Montréal, Canada.
2
Centre for Studies on the Prevention of Alzheimer's Disease, Douglas Mental Health University Institute, Montréal, Canada; McGill University, Montréal, Canada. Electronic address: sylvia.villeneuve@mcgill.ca.

Abstract

The advent of amyloid-beta (Aβ) positron emission tomography (PET) imaging has transformed the field of Alzheimer's disease (AD) by enabling the quantification of cortical Aβ accumulation and propagation in vivo. This revolutionary tool has made it possible to measure direct associations between Aβ and other AD biomarkers, to identify factors that influence Aβ accumulation and to redefine entry criteria into clinical trials as well as measure drug target engagement. This chapter summarizes the main findings on the associations of Aβ with other biomarkers of disease progression across the AD spectrum. It discusses investigations of the timing at which Aβ pathology starts to accumulate, demonstrates the clinical utility of Aβ PET imaging and discusses some ethical implications. Finally, it presents genetic and potentially modifiable lifestyle factors that might influence Aβ accumulation and therefore be targets for AD prevention.

KEYWORDS:

Alzheimer's disease; Amyloid; Diagnosis; Imaging; PET; Pathology; Prevention

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center